OneDigital Investment Advisors LLC Sells 27 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

OneDigital Investment Advisors LLC lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 563 shares of the company’s stock after selling 27 shares during the period. OneDigital Investment Advisors LLC’s holdings in IDEXX Laboratories were worth $233,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $29,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories in the 4th quarter worth $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories in the 4th quarter worth $31,000. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories in the 4th quarter worth $38,000. Finally, Crews Bank & Trust bought a new stake in IDEXX Laboratories in the 4th quarter worth $41,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.8 %

Shares of NASDAQ:IDXX opened at $433.99 on Tuesday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $548.88. The firm has a market capitalization of $35.17 billion, a P/E ratio of 40.67, a P/E/G ratio of 3.41 and a beta of 1.50. The stock has a 50 day moving average price of $419.59 and a 200-day moving average price of $428.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent analyst reports. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Piper Sandler raised their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research report on Monday, April 14th. Finally, Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $523.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.